Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
The replacement of bleomycin with the immune drug conjugate brentuximab vedotin in the first-line chemotherapy regimen for advanced Hodgkin’s lymphoma prolonged both progression-free and overall survival.
Saved in:
Published in | The New England journal of medicine Vol. 387; no. 4; pp. 310 - 320 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Boston
Massachusetts Medical Society
28.07.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The replacement of bleomycin with the immune drug conjugate brentuximab vedotin in the first-line chemotherapy regimen for advanced Hodgkin’s lymphoma prolonged both progression-free and overall survival. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 ObjectType-News-3 content type line 23 |
ISSN: | 0028-4793 1533-4406 |
DOI: | 10.1056/NEJMoa2206125 |